A long time ago, people used to smoke a plant called cannabis just to feel high. But now, they want more. They want different ways to use the plant that make them feel better in special ways. For example, some cannabis products help you sleep better, while others help with pain or stress. This makes the cannabis industry grow and change a lot. One of the new things they are looking at is something called rare cannabinoids. These are parts of the plant that have different effects on how people feel. People who make cannabis products want to find these special parts and use them to create better stuff for customers. There is a big meeting where everyone talks about this, and it's very important for the future of cannabis. Read from source...

- The title is misleading and clickbait, as it implies that there is a secret or hidden truth under the microscope, when in reality, the article is just describing some general trends and developments in the cannabis industry.
- The article lacks proper citation of sources, data, and evidence to support its claims and assertions. It relies on vague terms like "surge", "evolves", "shifting focus", etc., without providing any specific numbers or references to back them up.
- The article uses a lot of jargon and technical terms that may not be familiar or clear to the average reader, such as terpenes, flavonoids, minor cannabinoids, rare canabinoids, etc. It does not explain what they are, how they work, or why they matter for consumers and products.
- The article has a strong bias towards the positive aspects of cannabis products, and ignores or downplays the potential risks, drawbacks, or limitations of some of these new trends and innovations. For example, it does not mention any possible side effects, interactions, legal issues, or ethical concerns related to using different cannabinoids or formulations.
- The article is mainly promoting an event sponsored by Benzinga, without disclosing this conflict of interest to the readers. It uses the event as a source of authority and credibility, but it also tries to sell tickets to the readers at the end of the article, which is inappropriate for a news platform.